Intervention not reported
MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination (Priorix‐Tetra) · children 9 months to 15 years old
The intervention showed no clear difference in MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination… (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR ‐ by brand ‐ from 7 to 10 days after vaccination (Priorix‐Tetra) · children 9 months to 15 years old
The intervention may leads to higher MMRV vs MMR ‐ by brand ‐ from 7 to 10 days after vaccination… (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination (ProQuad) · children 9 months to 15 years old
The intervention may leads to higher MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination (ProQuad) (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR ‐ by brand ‐ from 7 to 10 days after vaccination (ProQuad) · children 9 months to 15 years old
The intervention may leads to higher MMRV vs MMR ‐ by brand ‐ from 7 to 10 days after vaccination (ProQuad) (low certainty).
1 finding from 1 review
Intervention not reported
Cohort studies ‐ all children, MMR · children 9 months to 15 years old
The intervention showed no clear difference in cohort studies ‐ all children, MMR (moderate certainty).
1 finding from 1 review
Intervention not reported
Cohort studies ‐ autism risk (low), MMR · children 9 months to 15 years old
The intervention showed no clear difference in cohort studies ‐ autism risk (low), MMR (moderate certainty).
1 finding from 1 review
Intervention not reported
Cohort studies ‐ Jeryl Lynn strain ‐ 1 dose · children 9 months to 15 years old
The intervention probably leads to lower cohort studies ‐ Jeryl Lynn strain ‐ 1 dose (moderate certainty).
1 finding from 1 review
Intervention not reported
Cohort studies ‐ autism risk (moderate/high), MMR · children 9 months to 15 years old
The intervention may leads to lower cohort studies ‐ autism risk (moderate/high), MMR (low certainty).
1 finding from 1 review
Intervention not reported
Case control ‐ all IBD, MMR · children 9 months to 15 years old
The intervention showed no clear difference in case control ‐ all IBD, MMR (moderate certainty).
1 finding from 1 review
Intervention not reported
Case control ‐ ulcerative colitis, MMR · children 9 months to 15 years old
The intervention showed no clear difference in case control ‐ ulcerative colitis, MMR (moderate certainty).
1 finding from 1 review
Intervention not reported
Case control ‐ Crohn's disease, MMR · children 9 months to 15 years old
The intervention probably leads to lower case control ‐ Crohn's disease, MMR (moderate certainty).
1 finding from 1 review
Intervention not reported
Cohort study ‐ MDI‐BSID II 24th month, MMR · children 9 months to 15 years old
The intervention showed no clear difference in cohort study ‐ MDI‐BSID II 24th month, MMR (low certainty).
1 finding from 1 review
Intervention not reported
Cohort study ‐ MDI‐BSID II 36th month, MMR · children 9 months to 15 years old
The intervention showed no clear difference in cohort study ‐ MDI‐BSID II 36th month, MMR (low certainty).
1 finding from 1 review
Intervention not reported
Cohort study ‐ Raven 5th year, MMR · children 9 months to 15 years old
The intervention showed no clear difference in cohort study ‐ Raven 5th year, MMR (low certainty).
1 finding from 1 review
Intervention not reported
Cohort study ‐ WISC‐R verbal 6th year, MMR · children 9 months to 15 years old
The intervention showed no clear difference in cohort study ‐ WISC‐R verbal 6th year, MMR (low certainty).
1 finding from 1 review
Intervention not reported
Case‐control ‐ case cross‐over ‐ case controls MMR · children 9 months to 15 years old
The intervention may leads to higher case‐control ‐ case cross‐over ‐ case controls MMR (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ MMR vaccine ‐ age from 9 to 23 months · children 9 months to 15 years old
The intervention probably leads to higher self‐controlled case series ‐ MMR vaccine ‐ age from 9 to 23 months (moderate certainty).
1 finding from 1 review
Intervention not reported
Cohort studies ‐ Jeryl Lynn strain ‐ 2 doses · children 9 months to 15 years old
The intervention probably leads to lower cohort studies ‐ Jeryl Lynn strain ‐ 2 doses (moderate certainty).
1 finding from 1 review
Intervention not reported
Case‐control ‐ MMR vaccine · children 9 months to 15 years old
The intervention may leads to higher case‐control ‐ MMR vaccine (low certainty).
1 finding from 1 review
Intervention not reported
Cohort study MMR ‐ all children · children 9 months to 15 years old
The intervention showed no clear difference in cohort study MMR ‐ all children (low certainty).
1 finding from 1 review